The role of osimertinib in the therapeutic pathway of EGFR-mutated NSCLC: results from an Italian Delphi Consensus
- DOI
- 10.33393/grhta.2026.4055
- Published
- 2026-11-04
- Container
- Global and Regional Health Technology Assessment
- Publisher
- Aboutscience Srl
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.33393/grhta.2026.4055,
title = {The role of osimertinib in the therapeutic pathway of EGFR-mutated NSCLC: results from an Italian Delphi Consensus},
author = {Andrea Ardizzoni and Ilaria Attili and Federico Cappuzzo and Andrea De Giglio and Filippo De Marinis and Maristella Giammaruco and Cesare Gridelli and Vito Ladisa and Paolo Maione and Silvia Novello and Francesco Passiglia and Federica Maiocchi and Edoardo Sanna and Roberto Ravasio},
year = {2026},
journal = {Global and Regional Health Technology Assessment},
doi = {10.33393/grhta.2026.4055},
url = {https://doi.org/10.33393/grhta.2026.4055}
}RIS
TY - JOUR TI - The role of osimertinib in the therapeutic pathway of EGFR-mutated NSCLC: results from an Italian Delphi Consensus AU - Andrea Ardizzoni AU - Ilaria Attili AU - Federico Cappuzzo AU - Andrea De Giglio AU - Filippo De Marinis AU - Maristella Giammaruco AU - Cesare Gridelli AU - Vito Ladisa AU - Paolo Maione AU - Silvia Novello AU - Francesco Passiglia AU - Federica Maiocchi AU - Edoardo Sanna AU - Roberto Ravasio PY - 2026 JO - Global and Regional Health Technology Assessment DO - 10.33393/grhta.2026.4055 UR - https://doi.org/10.33393/grhta.2026.4055 ER -
APA
Ardizzoni, A., Attili, I., Cappuzzo, F., Giglio, A. D., Marinis, F. D., Giammaruco, M., Gridelli, C., Ladisa, V., Maione, P., Novello, S., Passiglia, F., Maiocchi, F., Sanna, E., & Ravasio, R. (2026). The role of osimertinib in the therapeutic pathway of EGFR-mutated NSCLC: results from an Italian Delphi Consensus. Global and Regional Health Technology Assessment. https://doi.org/10.33393/grhta.2026.4055
Source records
- crossref · retrieved 2026-11-09T10:25:37.024Z